Taipei, Taiwan

Chang-Hsin Shi

This inventor holds 1 USPTO granted patent. Top assignee: Dr. Keith Chan, Globoasia, LLC. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chang-Hsin Shi. Retrieved from https://idiyas.com/inventor/chang-hsin-shi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chang-Hsin Shi: Innovator in Pharmaceuticals

Introduction

Chang-Hsin Shi is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative research and development efforts.

Latest Patents

Chang-Hsin Shi holds a patent for the "Synthesis and pharmaceuticals of novel 9-substituted-1, 5-dichloroanthracene analogs." This patent showcases his expertise in creating new pharmaceutical compounds that may have important applications in medicine.

Career Highlights

Throughout his career, Chang-Hsin Shi has worked diligently in the pharmaceutical industry. He is currently associated with Dr. Keith Chan at Globoasia, LLC, where he continues to push the boundaries of pharmaceutical research.

Collaborations

Chang-Hsin Shi has collaborated with talented individuals such as Hsu-Shan Huang and Kung-Yuan Lee. These partnerships have further enhanced his research capabilities and contributed to the success of his projects.

Conclusion

Chang-Hsin Shi is a dedicated inventor whose work in pharmaceuticals has the potential to impact the industry significantly. His innovative spirit and collaborative efforts continue to drive advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…